Interestingly, we observed a trend toward increased CD8+ T cell cytokine production in anti-CD20 mAb–treated patients compared with untreated patients with MS, which was significantly increased in the case of IFN-γ+ CD8+ T cells in both anti-CD20 mAb cohorts. The gene discussed is CD8A; the disease is myeloid sarcoma.